If you have been reading about Incretin hormone and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-07. Numbers and descriptions here follow the published literature rather than marketing material.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Free base form |
| Molecular mass | Approximately 4813 Da | Calculated from the sequence |
| Amino acid residues | 39 | GIP-derived backbone |
| Receptor targets | GIP and GLP-1 | Dual agonist |
| Circulating half-life | About 5 days | Supports weekly administration |
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
=== 23 March === Eleven people were killed in an RSF drone strike on the Radwan Mosque in Hilat Kuko in East Nile area of Khartoum. Eight people were killed by RSF shelling in El Fasher, while three others were killed by RSF shelling in Omdurman. Eighteen people were killed following three days of RSF attacks on villages in Gezira State northwest of Wad Madani. The RSF claimed to have taken Lagawa in West Kordofan.
Center for Medicare (CM) Center for Medicaid and CHIP Services (CMCS) Center for Medicare and Medicaid Innovation (CMMI, a.k.a. the CMS Innovation Center) Center for Consumer Information and Insurance Oversight (CCIIO) Center for Program Integrity (CPI) Center for Clinical Standards and Quality (CCSQ) The regions:
== Redox-Neutral Radical Cross-Coupling == In 2025, the Baran laboratory reported a general platform for "redox-neutral radical cross-coupling" employing sulfonyl hydrazides as stable, crystalline radical precursors. These reagents, prepared from a variety of feedstocks (including alcohols, carbonyl compounds, amines, and hydrazines), function as dual-purpose agents: they generate alkyl radicals while donating electrons to activate the nickel catalyst. This eliminates the need for external redox additives, photoredox catalysts, electrochemical setups, or pyrophoric organometallic reagents. The reactions operate under Suzuki-like conditions—an inexpensive nickel catalyst, mild base, and gentle heating—with nitrogen gas as the sole byproduct. The platform enables C–C bond-forming transformations with multiple partner classes, including activated olefins (Giese-type additions), alkyl halides, redox-active esters, (hetero)aryl halides, alkenyl halides, alkynyl halides, and trifluoromethylating reagents. These couplings forge C(sp³)–C(sp³), C(sp³)–C(sp²), and C(sp³)–C(sp) bonds and have been adopted in medicinal chemistry programs for the rapid assembly of complex, sp³-rich scaffolds and fragment libraries. Later in 2025, the same sulfonyl hydrazide platform was extended to achieve stereospecific (stereoretentive) radical cross-couplings. Using readily accessible enantioenriched sulfonyl hydrazides and an achiral nickel catalyst, the method delivers high levels of stereoretention through an inner-sphere mechanism.
Sources: en.wikipedia.org
Double-blind trials have shown no difference in behavior between children given sugar-full or sugar-free diets, even in studies specifically looking at children with attention deficit hyperactivity disorder or those considered sensitive to sugar. A 2019 meta-analysis found no positive effect of sugar consumption on mood but did find an association with lower alertness and increased fatigue within an hour of consumption, known as a sugar crash. Sugar can, however, lead to a jump in blood sugar levels, and may make a child more active even if it does not cause clinical hyperactivity. Eating nuts, popcorn, or seeds does not increase the risk of diverticulitis. These foods may actually have a protective effect. Eating less than an hour before swimming does not significantly increase the risk of experiencing muscle cramps, and does not increase the risk of drowning. One study shows a correlation between alcohol consumption and drowning, but not between eating and stomach cramps. Vegan and vegetarian diets can provide enough protein for adequate nutrition. In fact, typical protein intakes of ovo-lacto vegetarians meet or exceed requirements. The American Dietetic Association maintains that appropriately planned vegetarian diets are healthful. However, a vegan diet does require dietary supplements. Swallowed chewing gum does not take seven years to digest. Chewing gum is mostly indigestible, and passes through the digestive system at the same rate as other matter.
However, owing to problems in administration and after several cases of unhealthiness, the Domino's Peruvian franchise closed in 2015, and reopened one year later with new owners. The master franchises for India, Nepal, and Sri Lanka are currently owned by the Indian company Jubilant FoodWorks. India is the largest international market for Domino's outside its home market, being the only country to have more than 1,000 Domino's outlets. With the first store opening in Delhi in 1996, the company operates 1,362 stores across 264 Indian cities as of 2018. In Bangladesh, the franchises for Domino's Pizza are co-owned by Jubilant FoodWorks and Golden Harvest Limited, forming 'Domino's Pizza Bangladesh Limited'. In this entity, Jubilant FoodWorks is the majority shareholder and owns 51% of the company, while the rest of the share is owned by Golden Harvest Limited. The first store in Bangladesh opened in February 2019. As of October 19 2017, Domino's Pizza opened in Naxxar Road Birkirkara, Malta. As of July 27, 2020, Domino's Pizza opened in downtown Zagreb, Croatia. As of 2020, Domino's Pizza opened 550 stores in Turkey. In Italy, Domino's declared bankruptcy closing all its stores. In Russia, DP Eurasia announced that they would be declaring bankruptcy for its Russian business and would be closing all of its locations in Russia, Turkey, Azerbaijan, and Georgia. The Russian network was bought by rapper Timati in August 2023. After the sale, it changed its name to Domиno Pizza.
melanogaster a mild heat shock pretreatment which induces heat shock gene expression (and greatly enhances survival after a subsequent higher temperature heat shock) primarily affects translation of messenger RNA rather than transcription of RNA. Heat shock proteins are also synthesized in D. melanogaster during recovery from prolonged exposure to cold in the absence of heat shock. A mild heat shock pretreatment of the same kind that protects against death from subsequent heat shock also prevents death from exposure to cold.
Sources: en.wikipedia.org
– indicates that no information is available As a result of heparin's effect on such a wide variety of disease states, a number of drugs are indeed in development whose molecular structures are identical or similar to those found within parts of the polymeric heparin chain.
EDC couples primary amines, and other nucleophiles, to carboxylic acids by creating an activated ester leaving group. First, the carbonyl of the acid attacks the carbodiimide of EDC, and there is a subsequent proton transfer. The primary amine then attacks the carbonyl carbon of the acid which forms a tetrahedral intermediate before collapsing and discharging the urea byproduct. The desired amide is obtained.
=== Misinformation === Naloxone has been subject to much inaccurate media reporting and many urban legends about it have become prevalent. One such myth is that naloxone makes the recipient violent. Another is that events called "Lazarus parties" have taken place, in which people reportedly took fatal overdoses in anticipation of being treated with naloxone; in reality this was a fiction spread by the police. Yet another is the claim that people have indulged in "yo-yoing", whereby they would take naloxone and opioids simultaneously to enjoy an extreme "high" and subsequent revival; the idea is scientifically nonsensical.
Sources: en.wikipedia.org
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.
A fatty diacid side chain promotes binding to albumin, which delays clearance from circulation. The half-life of roughly five days makes a weekly schedule practical.
No. It is a synthetic peptide whose backbone is based on the natural incretin hormone GIP. Non-natural residues and the lipid side chain were engineered to improve stability and duration of action.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.